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Impact of Moderating Model of the Risk in the Chronic Renal Disease.
IPS COMFANDI, Cali, 2006
LUIS MARIANO OTERO, M.D.1 ,2, ALVARO MUÑOZ, M.D.1 ,3, LUNEVAR F IGUEROA, M.D.1
SUMMARY
Objective: To assess if a health care model implemented at the basic level of the IPS COMFANDI and based on an early
intervention in cardiovascular risk factors and its application to patients with different levels of chronic renal disease, produces
significant changes in lab and clinical parameters to be translated into stabilization or regression of the disease.
Materials and methods: From the cardiovascular risk program 362 patients were randomly selected with different stages of renal
disease, diabetes mellitus (DM), and arterial hypertension, (AHT). Two measurements were made: one before and another after
the intervention, with an interval of six months. Wilcoxon hypotheses were tested to compare means of clinical interest and lab
variables as well as dynamics of change in the number of patients according to KDOQUI stage, for both periods.
Results: A total of 8 factors were evaluated: 4 clinical and 4 lab parameters, as well as patients’ proportion according to
nephropathy stage (KADOQUI) found in the two periods. Clinical variables were measured for 24 hours such as systolic, diastolic
and mean blood pressure and proteinuria which showed differences before and after the intervention that were statistically
significant. BMI (body mass index), glycemia and microalbu-minuria did not present statistically significant differences for the two
measurements.
Conclusion: Implementation of a basic level health care model focused on risk reduction for renal chronic disease, by means
of an intensive therapy, has also an affirmative incidence on diseases such as diabetes and hypertension. Results are favorable
when measuring key variables in renal chronic disease and suggest a positive impact regarding this important public health problem
in Colombia.
Keywords: Primary prevention; Natural history of the disease; Testing hypothesis; Regression;
Stabilization; Epidemiological transition.
Impacto del Modelo Moderador del Riesgo en la Enfermedad Renal Crónica. IPS COMFANDI, Cali, 2006
RESUMEN
Objetivo: Evaluar si un modelo de atención que se lleva a cabo en el nivel básico de la IPS COMFANDI y se fundamenta en
una intervención temprana de factores de riesgo cardioavascular y aplicado a pacientes con distintos grados de enfermedad renal
crónica, genera cambios significantes en parámetros clínicos y de laboratorio que se traduzcan en estabilización o regresión de la
enfermedad.
Materiales y métodos: Se seleccionaron al azar 362 pacientes con diversos grados de enfermedad renal del programa de riesgo
cardiovascular (diabetes mellitus e hipertensión arterial, DM e HTA) con dos mediciones una antes y otra después de la intervención
con intervalo de por lo menos 6 meses. Se realizaron pruebas de hipótesis de Wilcoxon para comparar medianas de las variables
de interés clínico y de laboratorio así como la dinámica de cambio en la proporción de pacientes según estadío KDOQUI en ambos
tiempos.
Resultados: En total se evaluaron 8 parámetros, 4 clínicos y 4 de laboratorio, así como la proporción de pacientes según estadío
de nefropatía (KADOQUI) entre un tiempo y el otro. En las variables clínicas como tensión arterial sistólica, diastólica, media y
proteinuria en 24 h, las diferencias encontradas entre antes y después de la intervención tuvieron significancia estadística. Pero,
1. Physician, Caja de Compensación Familiar (COMFANDI), Quality Assurance Department, Subdirección de Salud, Cali,
Colombia. e-mail: lunevar@yahoo.com
2. Coordinator of Postgraduate Nephrology Program, Internal Medicine Department, Universidad del Valle, Cali, Colombia.
3. Epidemiologist, Colombian Foundation for Brain Trauma Management (FUNDCOMA), Cali. Colombia.
e-mail: alvaro.munozc@telecom.com.co
Recibido para publicación enero 19, 2006      Aceptado para publicación julio 4, 2007
© 2007 Corporación Editora Médica del Valle                                                     Colomb Med 2007; 38: 282-289
283
Colombia Médica                     Vol. 38 Nº 3, 2007 (Julio-Septiembre)
tanto en el índice de masa corporal (IMC) como en la glucemia
y la microalbuminuria no hubo diferencias estadísticamente
significantes entre las dos mediciones.
Conclusión: La puesta en marcha de un modelo de atención
en el nivel básico, que se centre en disminuir el riesgo de
desarrollar enfermedad renal crónica, por medio de una terapia
intensiva, en enfermedades como DM e HTA, produce resulta-
dos favorables en las segundas mediciones de variables clave
de la enfermedad renal crónica y sugiere un impacto positivo en
este problema de salud pública en Colombia.
Palabras clave: Prevención primaria; Historia natural de la
enfermedad; Pruebas de hipótesis; Regresión;
Estabilización; Transición epidemiológica.
In Colombia a transition process is taking place regarding
population growth and epidemiology with lower fertility
rates and higher life expectancy. However, the disease
load is characteristic of developing countries such as acute
diarreic disease, maternal mortality, etc., higher morbility
and disabilities due to chronic diseases and their
consequences1.
Chronic renal disease incidence in LatinAmerica and
Colombia has had an unprecedented growth similar to
levels found in industrialized societies. At present, in the
city of Cali and Valle Department (State), more than one
thousand patients are receiving dyalisis, accounting for
almost 15% of all patients in Colombia. The Hospital
Universitario del Valle has doubled the cases of terminal
renal failure during 2001 and 2002 when compared to 1999
and 20002.
Health care institutions face a challenge because the
health prevention approach has to continue as well as the
definition of effective strategies that respond to the inte-
gral management of chronic entities such as hypertension
and diabetes, diseases specific to elderly people that tradi-
tionally have been a matter of concern only to developed
countries.
Since health care to these patients implies a high cost
that the health care system finds difficult to be compensated,
researchers have gone beyond the understanding of the
natural history of the disease looking for alternatives that
may have a timely impact with a cost-effective approach.
This is the reason to adopt a model that emphasizes
intervention on cardiovascular risk3 factors in order to
have an early incidence on chronic renal disease.
Among other aspects, this model has a practical
approach regarding:
· Specific therapy based on diagnosis
· Evaluation and management of morbid conditions going
with
· Delay in renal function loss
· Cardiovascular disease prevention and treatment
· Renal function reduction prevention and treatment of
complications
An intensive therapy characterized by a strict control
of glucose in diabetic people and blood pressure in
hypertensive patients in order to improve glomerular rate
filtration (GRF) or creatinine clearance4.
This therapy is implemented by nephrologists strate-
gically located in primary health care centers who have
trained general physicians and with almost exclusive
medication from the obligatory health plan (OHP), have
been able to enhance solutions by integrating inclusion and
patient follow-up processes from a biopsicosocial pers-
pective.
According to the epidemiological profile (Muñoz A.,
October 2006 unpublished data) at COMFANDI from a
total of 230,000 members affiliated, 10% have a diagnosis
of chronic arterial blood hypertension and 2% diabetes
mellitus, and an intermediate group of 6% to 7% of patients
with different levels of renal function reduction (nephro-
pathy).
The definition of renal chronic disease (not renal
failure) in accordance with K/DOQUI4-6 (kidney disease
outcomes quality initiative) is:
1. Renal failure for more than three months, considered
as structural or functional kidney abnormalities with or
without GFR (glomerular filtration rate) decrease.
2. GFR below 60 ml/min, 1.73 m2 for a period over three
months with or without evidence of kidney dammage.
In this case, GFR was considered as the output variable
(GFR normal value 60 to 120 ml/min/1.73).
The working hypothesis assumes that the so called risk
moderating model is able to produce a favorable impact in
renal chronic disease. This is demonstrated by propitious
changes in clinical and lab parameters between the two
measurements (before and after) y is translated into
Remission or Regression of this pathology (Table 1)6-9.
MATERIALS AND METHODS
Retrospective data were collected from clinical histo-
ries of patients attending regularly the cardiovascular risk
program in nine (9) primary IPSs from COMFANDI
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between 2005 and 2006.
Inclusion criteria were male and female patients having
a certain stage of chronic renal disease with two GFR
measurements, one at time zero and the second one at
least six months after starting the intervention.
Following KDOQUI recommendations to estimate
GFR in patients with a renal chronic disease, the prediction
equation based on creatinine or the «Cockcroft-Gault
equation»5-6 was used, because it gave a more accurate
measurement and includes variables such as age, sex and
additionally incorporating 100% of observations.
KDOQUI establishes that the loss of physiological
GFR associated to aging is 1 ml/min/1.73 per year and it
defines an accelerated deterioration of renal function as a
loss of 4 ml or more per minute per year.
As it was decided to assess stabilization and/or
regression in a six month period, 2 ml were considered as
the minimal difference to be found between the
measurements. Independent variables were 8 in total: 4
clinical and 4 lab (Cuadro 2).
Dependent variable  was creatinine clearance or GFR,
expressed as 1 to 5 gradients that increase their value
according to severity in renal function loss, where 1
represents the lowest value and 5 an indication for dyalisis:
Stage 1 = GFR normal or above 90 ml/min/1.73m2
Stage 2 = GFR 60 to 89
Stage 3 = GFR 30 to 59
Stage 4 = GFR 15 to 29
Stage 5 = GFR <15
Statistical analysis. In 2005 from 13,216 patients
included in the cardiovascular risk program with a diagno-
sis of hypertension and/or diabetes, in around 6 % (792) a
certain degree of kidney chronic disease6-16 was found.
Since it was expected to find small differences such as
a GFR of 2 ml from the first to the second measurement,
with an 89% power, a 95% significance and a 0.9 correlation
ratio, 360 patients had to be taken in.
As a compensation for losses sample size was increased
by 10%, and 396 patients were selected through a simple
random sampling; among them 34 were excluded because
they lacked one of the two measurements and 362 were
included in the final analysis.
The study design was a «before and after» analysis
with «no control group», each subject was his own control.
Wilcoxon allocated range test was used, considering the
large sample size (n>15) and the fact that the addition of
ranges is normally distributed and as a result z statistical
analysis18,19 was utilized.
First, an univariate analysis of population characteristics
such as age, weight and independent variables was carried
out including a comparison of means, medians and stan-
dard deviation with a gender control. Later, age and
weight performance were analyzed according to gender
and IPS.
Then, correlation charts were drawn for systolic,
diastolic and mean blood pressures and for GFRs for both
periods and including gender stratification.
Wilcoxon allocated range tests were carried out for
each of the clinical and lab variables in the two periods.
Finally, to determine the rate of patients migrating
Table 1
Definition of progression, remission, and  regression of proteinuric chronic nephropathies
        Variables    Progression  Remission Regression
Proteinuria >1g/24h <g/24h <0.3g/24h
GFR (ml/min/m2) Reduction* Stabilization Increase
Changes in renal structure Deterioration Stable Improvement
* Reduction: higher than age related reduction (1ml/min/1.73 per month)
   Clinical variables    Normal range   Laboratory variables       Normal range
BMI (body mass index) 18 a 25% Creatinine 0.7 a 1.3 mg /dl
SBP (systolic blood pressure) 140 mm Hg Microalbuminuria <17 mg/l
DBP (diastolic blood pressure) 90 mm Hg Fasting blood sugar 60 a 110 mg%
MBP (mean blood pressure) 80-120 mm Hg Proteinuria 24h Up tp 0.1 g/dl
Table 2
Independent  variables and normal range
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within their category from time zero and postintervention,
GFR variable was grouped in 5 categories (kadoqui) and
was likened by means of a ratio comparison test with chi2.
STATA 8.0 statistical package was applied through all
of the statistical analysis.
RESULTS
Tables 3 and 4 present the summary for clinical and lab
variables. From a total of 362 individuals, 214 (60%) were
males and 148 (40%) females, with a mean age of 64
years for both groups. In average, males were 12 cm taller
than females.
For both groups, median age was 63 years. However,
at the Candelaria IPS the mean age was 48 and the median
49 years, the youngest group. Average weight for all the
population was 71 kg during both measurements but it was
higher in males (74 kg) when compared to females (66
kg).
Clinical parameters. In relation to BMI, a mean of
27.5% and a median of 26.89 was obtained for the first
period and a value of 27.72 for the second one. These
differences are statistically significant (p=0.03) although
the patients remained within the same overweight category
(BMI = 25% to 29%)
Median systolic blood pressure (SBP) presented a
significant reduction of 8 mm Hg from to the first to the
second measuremnt (p=0.000).
Although in diastolic blood pressure (DBP) the median
was similar for both measurements when age stratification
was used, it was found that only in the 15 to 44 group or
only in 36 subjects of the population under study, there
were no differences (p=0.8), while in groups from 45 to 64,
65 to 74 and 75 and over, differences were significant from
the first measurement to the second one (p=0.000).
Mean blood pressure (MBP) was reduced by 5 mm Hg
in the median between the first and second measurements,
and represented a 5% significance (p=0.000).
In both periods, the rate of reduction of SBP was higher
when compared to DBP and MBP (Table 5).
Laboratory parameters. For creatinine, even if data
had a small reduction from time 1 (1.37 mg%) to time 2
(1.26 mg%), this reduction was enough to show statistically
significant differences (p=0.000).
After the intervention, mean and median values were
lower for microalbuminuria but overall there was not an
   Variable                   N                   Media      Media         Median          Median
              F          IC 95% M              IC 95%   F             IC 95%      M           IC 95%
 BMI 2 (kg/m2) 357 28.31 27-29 27.09 26.57-27.61 27.76 27-29 26.56 26.21-27.05
 SBP 2 (mm Hg) 362 128.06 125-131 126.58 124-129 128.0 120-130 120.0 120-130
 DBP 2 (mm Hg) 362 75.37 74-77 76.99 76-78 73.0 70-80 80.0 75-80
 MBP 2 (mm Hg) 362 92.93 91-95 93.52 92-95 92.66 90-93 91.33 90-93
 Creat 2 (mg%) 362 1.28 1.15-1.42 1.6 1.47-1.74 1.07 0.99-1.16 1.36 1.30-1.41
 Microalbuminuria 2 39 80.41 9-152 81.74 44-119 15.85 8.0 - 31 58.0 9-127
 Gluc 2 (mg%) 142 133.85 120-149 139.73 128-152 118.0 110-127 121.5 116-132
 Proteinuria 24 h 2 184 535.05 317-753 579.81 347-813 205.34 118-258 175.4 137-215
Table 4
Summary of univariate statistics after intervention, gender stratification, COMFANDI-Cali, 2006
Table 3
Summary of univariate statistics before intervention, gender stratification, COMFANDI-Cali, 2006
   Variable                   N                   Media      Media         Median          Median
              F          IC 95% M              IC 95%   F             IC 95%      M           IC 95%
 BMI 1 (kg/m2) 357 28.21 27-29 26.95 26.46-27.43 27.99 26-29 26.56 26-27
 SBP 1 (mm Hg) 362 133.39 130-137 132.13 129-135 130 128-131 130 128-130
 DBP 1 (mm Hg) 362 78 76-80 80.49 79-82 80 72-80 80 80-80
 MBP 1 (mm Hg) 362 96.46 94-99 97.70 96-99 95.16 93-97 96.66 94-97
 Creat 1 (mg%) 362 1.32 1.22-1.43 1.59 1.47-1.72 1.13 1.05-1.21 1.41 1.38-1.47
 Microalbuminuria 1 63 185.79 85-287 174.53 87-263 31 25-260 44.75 26-98
 Gluc 1 (mg%) 179 145.02 128-161 134.62 125-144 122 111-139 120 112-128
 Proteinuria 24 h 1 266 638.7 451-826 600.59 401-744 255.9 234-302 240 210-251
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important reduction (p=0.15). This finding did not change
when gender and age groups stratification were imple-
mented.
Microalbuminuria presented the lowest number of
paired data (39) with a wide range, data scattering and a
variation ratio of 137%.
For fasting blood sugar, the median for time 1 was 120
mg% and postintervention reached 119 mg%, a 1 mg%
reduction not producing a statistically significant change
(p=0.24),but when a gender stratification was made a
reduction in females but not in males was found. In the
case of males, the mean and the median figures did not
vary from time 1 to time 2.
In relation to proteinuria at 24 hours, a significant
reduction was present (p=0.000) from 251 mg to 171
during time 2, although a large data scattering were
present with a variation ratio of 171%, a posible explanation
for the large range variation and the lower number of
observations (184).
In the result variable, GFR increased from time 1 to
time 2 with a median before the intervention of 52 ml/min/
m2 and after of 55 ml/min/m2, which was significant
(p=0.000). Gender stratification showed statistically
significant differences from time 1 to time 2 (female
p=0.000) (male p=0.000). Chart 1, shows similar results in
relation to statistical significance that were obtained when
stratifying per age group. Larger differences were found
for the median in the group from 15 to 44 years (Chart 2).
K/DOQUI stage. Category 3 presented the highest
prevalence, 49% for basal time and 42% after the
intervention. The intervention allowed migration of 24
patients in category 3 in time 1 to time 2, 18 showed a
regression, 15 to stage 2 and 3 to stage 1, the remaining
6 presented a progression, 4 to stage 4 and 2 to stage 5.
When implementing ratio comparison tests, it was found
that in the evolution of patients in time according to the
category, there was a marginal statistical significance
p=0.06 in category 3 of kdoqui classification; in other
categories differences were not significant (Table 6).
DISCUSSION
At present, in Colombia there are no similar publications
assessing the impact of an intervention in patients with
chronic kidney disease. This is the main strength of the
study.
Table 5
Changes in clinical and laboratory variables after the intervention, COMFANDI, Cali 2006
                   Variable                        N                                      Median
                         Before                   After                       z                     Value p
BMI (kg/m2) 357 26.89 26.72 -2.10 0.30
SBP (mm Hg) 362 130 122 4.36 0.000
DBP (mm Hg) 362 80 80 4.66 0.000
MBP (mm Hg) 362 96.66 92 5.23 0.000
Creat (mg%) 362 1.37 1.26 4.50 0.000
Microalbuminuria 39 34.5 23.3 1.42 0.15
Gluc (mg%) 142 120 119 1.15 0.24
Proteinuria 24 h 184 251.35 171.4 5.83 0.000
 z=Wilcoxon allocated range test      p=0.05
Table 6
Temporal evolution of number of patients per category of chronic kidney disease, COMFANDI,
Cali 2006
                        Before  %               After %               Chi2                            Value p
Kdoqui 1 14 15 0.10 0.75
Kdoqui 2 24 28 1.41 0.23
Kdoqui 3 49 42 3.48 0.06
Kdoqui 4 11 12 0.12 0.72
Kdoqui 5 1 1 0.83 0.36
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p*= 0.000 p*= 0.000
Before After
F M
 p* = Wilcoxon allocated ranges test






























   15 a 44         45 a 64   65 a 74   75 y más
                                                                p* = Prueba de Wilcoxon de rangos asignados
Chart 2. GFR median before and after intervention based on age groups. COMFANDI, Cali, 2006
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The design did not include a control group for moral
reasons: it was not ethical to deprive patients from the
benefits of a therapy assessed as effective in other
countries, since biological responses are similar in all of the
human beings.
In public health, some interventions need to produce
rapid responses vis-à-vis a changing reality, therefore
programs must be implemented and/or evaluation designs
that can not always comply with all recommendations
from «lex art» in epidemiology. Besides, given the type of
intervention and the non-inclusion of a control group in the
design before and after the use of subjects as their own
control, the only option available was to control external
factors that may be a threat to the conclusions validity.
It is important that neither weight nor BMI showed a
reduction in the postintervention measurement although
the benefits of weight reduction to control blood pressure
and blood sugar levels in patients with cardiovascular
disease and/or metabolic syndrome were widely proved.
On the other hand, it is worth increasing the efforts to
capture patients in early stages of cardiovascular disease
even before the onset of renal function deterioration. As
it is shown on Chart 2, the group from 15 to 44 years had
the highest response in terms of a larger delta change in
GFR increase by 12 ml/min/m2.
In terms of K/DOQUI category classification, in this
study it was observed the highest prevalence of patients in
category 3 which was the only one showing an important
reduction in the number of patients from time 1 to 2.
Microalbuminuria was the co-variable with a lower
number of observations (39), as per protocol in
COMFANDI, this test is given only at month seventh after
the patient is officially included in the cardiovascular risk
program.
As a large number of patients had a diagnosis of
diabetes, it would be desirable in a future study to have
values for glycosilated hemoglobin as an additional marker
of patient evolution6-9.
Once a positive impact may be established for this
intervention, the next step would be to consider factors
related to this success.
There are several studies indicating a correlation
between chronic kidney disease and cardiovascular
disease6-16, in future cohorts it could be appropriate to
examine the relation between intervention and incidence
rates for cardiovascular disease.
CONCLUSION
Results in favor of an alternate hypothesis suggest that
it is likely that differences found could be due to intervention
and not to other foreign factors. In similar studies with a
larger period between the two measurements, it is expected
to find relevant differences in all the variables of interest.
Multiple conditions imposed by the public health reality
in Colombia, force to implement novelty health care
models that involve the best scientific evidence and are
susceptible of evaluation in terms of impact.
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